A high monocyte-to-lymphocyte ratio and a high platelet-to-lymphocyte ratio were predictive of poor OS in patients with advanced gallbladder cancer treated with chemotherapy.
Postoperative radiation therapy with adjuvant chemotherapy prolonged disease-free survival and overall survival in patients with locally advanced urothelial carcinoma.
In a study of patients receiving non-surgical treatment for localized upper tract urothelial carcinoma, radiation or chemotherapy provided no overall survival benefit.
Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.
New evidence suggests variation in the bacterial composition of urine is associated with response BCG among patients with non-muscle-invasive bladder cancer.
Researchers found no significant difference in 30-day postoperative complications between patients who received neoadjuvant chemotherapy and those who did not.
An established chemoradiation regimen is compared with gemcitabine and once-daily radiation in the selective bladder-sparing treatment of muscle-invasive bladder cancer.
A retrospective study found EGFR and HER2 overexpression associated with clinical features, such as tumor stage and tumor recurrence, in bladder cancer tissue.
In a recently published study, external beam radiation therapy for localized prostate cancer was associated with a 35% increased risk of bladder cancer compared with radical prostatectomy.
Patients at VA facilities with high-risk early-stage bladder cancer tend to have cystoscopic surveillance at frequencies similar to those with low-risk disease.
Gene expression of a biomarker linked to malignancies, found in stromal cells surrounding a tumor — not the tumor cells themselves — appears to prevent the action of checkpoint blockade.
Researchers assess the outcomes of 5517 patients with bladder cancer who underwent radical cystectomy with or without neoadjuvant radiotherapy or chemotherapy.
